Company Overview
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 345.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Dec 2025 Revenue of $139.74M (+120.0% YoY); net profit $-79.99M.
- Trailing 12 Months Year-on-year growth — revenue +324.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 345.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 344.98% |
| 1 Year: | 324.90% |
Stock Price Performance
| 1 Year: | +45.91% |
| 6 Months: | +12.12% |
| 3 Months: | +2.35% |
| 1 Month: | +5.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 345.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BEAM Beam Therapeutics Inc. R2K | 30.89 | -63.04 | $3.18B | 0.00% | -27.72% | -5.77% | 344.98% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 6.00K | 6.00K | 6.00K | 6.00K | 763.00K | 8.43M | 16.65M | 15.80M | 24.21M | 20.12M | 17.19M | 7.41M | 11.77M | 14.27M | 7.47M | 8.47M | 9.70M | 31.74M |
| Operating Income | -13.11M | -17.65M | -18.02M | -28.36M | -26.29M | -37.32M | -200.37M | -58.97M | -69.63M | -76.22M | -81.97M | -91.30M | -98.93M | -102.15M | -108.27M | -104.13M | -104.89M | -106.50M | -119.29M | -120.15M | -126.81M | -107.22M |
| Net Income | -13.61M | -17.86M | -19.00M | -30.46M | -34.22M | -34.45M | -201.56M | -76.25M | -28.12M | -69.21M | -71.95M | -109.58M | -96.46M | -82.78M | -96.09M | -98.67M | -91.05M | -96.67M | -108.33M | -102.29M | -112.73M | -94.32M |
| Diluted EPS | - | - | - | - | -0.69 | -0.69 | -3.35 | -1.23 | -0.42 | -1.01 | -1.02 | -1.56 | -1.33 | -1.08 | -1.22 | -1.21 | -1.11 | -1.17 | -1.23 | -1.00 | -1.10 | -0.91 |
| R&D Expense | 9.18M | 12.68M | 12.54M | 21.55M | 19.35M | 29.82M | 190.11M | 45.58M | 54.62M | 65.41M | 74.56M | 85.29M | 99.65M | 97.61M | 100.05M | 84.82M | 87.04M | 94.26M | 98.82M | 101.76M | 109.77M | 104.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 18.00K | 24.00K | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Operating Income | -75.15M | -132.76M | -392.46M | -338.48M | -176.49M | -415.57M | -383.69M |
| Net Income | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M |
| Diluted EPS | -14.05 | -4.19 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 |
| R&D Expense | 54.62M | 103.18M | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 156.10M | 451.68M | 1.47B | 1.34B | 1.46B | 1.10B | 1.48B |
| Total Equity | -117.41M | -201.10M | 245.56M | 826.74M | 733.47M | 981.33M | 733.54M | 1.24B |
| Cash & Equivalents | - | 37.22M | 162.17M | 559.99M | 232.77M | 435.89M | 281.97M | 294.94M |
| Total Liabilities | - | 55.15M | 206.12M | 647.72M | 608.24M | 478.38M | 370.28M | 242.82M |
| Current Liabilities | - | 29.14M | 102.34M | 213.44M | 223.59M | 205.56M | 182.07M | 96.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -72.00M | -95.74M | -66.27M | 22.53M | -149.19M | -347.25M | -345.10M |
| Investing Cash Flow | -66.66M | -100.12M | -294.14M | -461.34M | 71.84M | 185.01M | -121.44M |
| Financing Cash Flow | 41.28M | 322.32M | 756.14M | 111.59M | 276.45M | 7.74M | 478.05M |
| Capital Expenditure | -12.52M | -16.36M | -46.81M | -48.95M | -33.73M | -8.95M | -14.95M |
| Free Cash Flow | -84.52M | -112.10M | -113.08M | -26.42M | -182.93M | -356.19M | -360.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -417,522.2% | -553,166.7% | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Net Margin % | -435,144.4% | -810,800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
| ROE % | 38.9% | -79.2% | -44.8% | -39.4% | -13.5% | -51.4% | -6.5% |
| ROCE % | -59.2% | -38.0% | -31.1% | -30.3% | -14.1% | -45.1% | -27.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.10% | 12.45M | $455.56M |
| 2 | ARK Investment Management, LLC | 11.79% | 12.13M | $443.90M |
| 3 | Farallon Capital Management LLC | 9.85% | 10.13M | $370.78M |
| 4 | Blackrock Inc. | 8.25% | 8.49M | $310.52M |
| 5 | State Street Corporation | 5.54% | 5.70M | $208.51M |
| 6 | Vanguard Portfolio Management LLC | 4.44% | 4.57M | $167.22M |
| 7 | Arch Venture Management, Llc | 4.41% | 4.54M | $166.10M |
| 8 | Vanguard Capital Management LLC | 4.25% | 4.38M | $160.15M |
| 9 | Sumitomo Mitsui Trust Group, Inc. | 3.72% | 3.83M | $139.96M |
| 10 | Amova Asset Management Americas Inc | 3.72% | 3.83M | $139.96M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BEAM
Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.…
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?
In late June 2026, an arbitration tribunal ruled that Prime Medicine did not breach its 2019 collaboration agreement with Beam Therapeutics and can continue developing PM647, an investigational gene-editing therapy for Alpha-1 Antitrypsin D…
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded.
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics.…
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medi…
BEAM — Frequently Asked Questions
What is the current share price of Beam Therapeutics Inc. (BEAM)?
As of 2026-07-14 21:23 PDT, Beam Therapeutics Inc. (BEAM) trades at $30.89 on NasdaqGS. Its 52-week range is $16.01 to $37.92.
What is the market capitalisation of BEAM?
Beam Therapeutics Inc. (BEAM) has a market capitalisation of $3.18B on NasdaqGS.
What is the P/E ratio of BEAM?
BEAM trades at a trailing price-to-earnings (P/E) ratio of -63.04. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.48.
What is the return on equity (ROE) of BEAM?
BEAM has a return on equity (ROE) of -5.77%. Its return on capital employed (ROCE) is -27.72%.
Is BEAM a good stock to buy?
This page provides a data-driven analysis of Beam Therapeutics Inc. (BEAM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.